Catalent announced this week that it is buying Masthercell, a global CDMO specializing in cell and gene therapies.
According to Catalent, the $315 million purchase of Belgium-based Masthercell will allow it to create an “industry-leading cell and gene therapy platform.”
Catalent, which provides delivery, development and manufacturing technologies for a range of products, strengthened its position in the gene therapy market last year with its $1.2 billion buyout of Paragon Services, which specializes in vaccines, oncology and gene therapies.
Now the company says that its purchase of Masthercell will extend will complement its gene therapy offerings and allow the company to “deliver comprehensive development, manufacturing, analytical, fill-finish, and clinical supply solutions for innovators across the large molecule space.”
According to the companies, Masthercell is in the midst of a 60,000-square foot expansion at its Belgium facility to add a dedicated commercial scale-production area and fill-finish facility. The new space will add over 250 jobs to the current team of 240. The company’s Houston facility is slated to also add 50 jobs by the end of the year once validation activities are completed.
Read the press release.
